Malaria
Conditions
Keywords
Artemether-lumefantrine, demographics, malaria
Brief summary
The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics, including evaluation of their malaria immune status, treatment effectiveness, prior and concomitant medication use, and the occurrence of adverse events in association with artemether-lumefantrine treatment, based on the information collected in the CDC Malaria Case Surveillance Report Form.
Interventions
OTHERArtemether-lumefantrine
Sponsors
Centers for Disease Control and Prevention
Novartis Pharmaceuticals
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the CDC. Malaria may be clinically suspected or confirmed (microscopically, and/or by polymerase chain reaction \[PCR\], and/or rapid diagnostic test \[RDT\]).
Exclusion criteria
* NA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness: Resolution of clinical signs and symptoms after artemether-lumefantrine treatment start | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event, serious adverse event after artemether-lumefantrine treatment start | 4 weeks |
| Pregnancies after artemether-lumefantrine treatment start | Up to delivery |
Countries
United States
Outcome results
None listed